Up until now biopharmaceutical drugs have been produced with the help of microorganisms. The new production building, the so-called Large Scale Cell Culture (LSCC), will make use of cell cultures for manufacturing purposes. This will enable significantly higher production volumes as well as the manufacturing of more complex active ingredients. The LSCC contains fermenters with a total volume of 185,000 litres. The facility can be converted from one product to another within an extremely short period of time and can also manufacture various products simultaneously.
Boehringer Ingelheim will produce the company's own products in the LSCC as well as serve as a contract manufacturer of drugs on behalf of other pharmaceutical companies. Drugs against heart attacks, strokes and cancer will be produced for Austria and the global market. Moreover, a logistics centre, a building for quality assurance and control, an energy control centre as well as a building for workshops and the company fire brigade were also constructed. The new complex encompasses 390,000 m³. 500 additional jobs for highly qualified employees were created on the basis of the expansion drive.
Continue reading and learn more about the life sciences location of Austria.